<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37532756</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Symptom profiles of community cases infected by influenza, RSV, rhinovirus, seasonal coronavirus, and SARS-CoV-2 variants of concern.</ArticleTitle><Pagination><StartPage>12511</StartPage><MedlinePgn>12511</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12511</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-38869-1</ELocationID><Abstract><AbstractText>Respiratory viruses that were suppressed through previous lockdowns during the COVID-19 pandemic have recently started to co-circulate with SARS-CoV-2. Understanding the clinical characteristics and symptomatology of different respiratory viral infections can help address the challenges related to the identification of cases and the understanding of SARS-CoV-2 variants' evolutionary patterns. Flu Watch (2006-2011) and Virus Watch (2020-2022) are household community cohort studies monitoring the epidemiology of influenza, respiratory syncytial virus, rhinovirus, seasonal coronavirus, and SARS-CoV-2, in England and Wales. This study describes and compares the proportion of symptoms reported during illnesses infected by common respiratory viruses. The SARS-CoV-2 symptom profile increasingly resembles that of other respiratory viruses as new strains emerge. Increased cough, sore throat, runny nose, and sneezing are associated with the emergence of the Omicron strains. As SARS-CoV-2 becomes endemic, monitoring the evolution of its symptomatology associated with new variants will be critical for clinical surveillance.</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geismar</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis and NIHR Health Protection Research Unit in Modelling and Health Economics, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK. c.geismar21@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK. c.geismar21@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragaszy</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Health Care, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrotri</LastName><ForeName>Madhumita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navaratnam</LastName><ForeName>Annalan M D</ForeName><Initials>AMD</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beale</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Epidemiology and Health Care, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Wing Lam Erica</ForeName><Initials>WLE</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yavlinsky</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovar</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Health Care, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoskins</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braithwaite</LastName><ForeName>Isobel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldridge</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayward</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Health Care, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC 19070</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>206602</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V028375/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>206602/Z/17/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="Y">Respiratory Syncytial Virus, Human</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>ACH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. The other authors declare no potential conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37532756</ArticleId><ArticleId IdType="pmc">PMC10397315</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-38869-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-38869-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gov.uk. COVID-19 Response: Living with COVID-19. In: Office C, editor. 2022.</Citation></Reference><Reference><Citation>Kim J-H, Roh YH, Ahn JG, Kim MY, Huh K, Jung J, et al. Respiratory syncytial virus and influenza epidemics disappearance in Korea during the 2020–2021 season of COVID-19. Int. J. Infect. Dis. 2021;110:29–35. doi: 10.1016/j.ijid.2021.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.07.005</ArticleId><ArticleId IdType="pubmed">34245886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodjat P, Christensen PA, Subedi S, Bernard DW, Olsen RJ, Long SW. The reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. Microbiol Spectr. 2021;9(2):e00430–e521. doi: 10.1128/Spectrum.00430-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00430-21</ArticleId><ArticleId IdType="pmc">PMC8557899</ArticleId><ArticleId IdType="pubmed">34494861</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC CfDCaP. Weekly U.S. Influenza Surveillance Report. 2022.</Citation></Reference><Reference><Citation>CDC. Preliminary Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States – 2021–2022 influenza season. 2022 04 October 2022.</Citation></Reference><Reference><Citation>Joint statement - Influenza season epidemic kicks off early in Europe as concerns over RSV rise and COVID-19 is still a threat [press release]. 01–12–2022 2022.</Citation></Reference><Reference><Citation>Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS ONE. 2020;15(6):e0234765. doi: 10.1371/journal.pone.0234765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0234765</ArticleId><ArticleId IdType="pmc">PMC7310678</ArticleId><ArticleId IdType="pubmed">32574165</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618–1624. doi: 10.1016/S0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: Sore throat, fatigue, and myalgia are more common with new UK variant. BMJ. 2021;372:n288. doi: 10.1136/bmj.n288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n288</ArticleId><ArticleId IdType="pubmed">33514508</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat. Commun. 2022;13(1):6856. doi: 10.1038/s41467-022-34244-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34244-2</ArticleId><ArticleId IdType="pmc">PMC9651890</ArticleId><ArticleId IdType="pubmed">36369151</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragaszy EB, Warren-Gash C, White PJ, Zambon M, Edmunds WJ, Nguyen-Van-Tam JS, et al. Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study. Influenza Other Respir. Viruses. 2018;12(1):171–182. doi: 10.1111/irv.12506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12506</ArticleId><ArticleId IdType="pmc">PMC5818341</ArticleId><ArticleId IdType="pubmed">28991409</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragaszy EB, Warren-Gash C, Wang L, Copas A, Dukes O, Edmunds WJ, et al. Cohort profile: The flu watch study. Int. J. Epidemiol. 2016;46(2):e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837336</ArticleId><ArticleId IdType="pubmed">26940466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward A, Fragaszy E, Kovar J, Nguyen V, Beale S, Byrne T, et al. Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: Protocol for Virus Watch, a prospective community cohort study. BMJ Open. 2021;11(6):e048042. doi: 10.1136/bmjopen-2020-048042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048042</ArticleId><ArticleId IdType="pmc">PMC8230990</ArticleId><ArticleId IdType="pubmed">34162651</ArticleId></ArticleIdList></Reference><Reference><Citation>UKHSA. Investigation of SARS-CoV-2 variants: technical briefings. 2022.</Citation></Reference><Reference><Citation>ECDC. Immune responses and immunity to SARS-CoV-2. European Center for Disewase Prevention and Control; 2021.</Citation></Reference><Reference><Citation>Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS ONE. 2021;16(3):e0247461. doi: 10.1371/journal.pone.0247461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247461</ArticleId><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>UKHSA. UKHSA SARS-CoV-2 reinfection guideline: Investigation and management of suspected SARS-CoV-2 reinfections. 2021.</Citation></Reference><Reference><Citation>Chen J, Wang R, Gilby NB, Wei G-W. Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J. Chem. Inform. Model. 2022;62(2):412–422. doi: 10.1021/acs.jcim.1c01451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c01451</ArticleId><ArticleId IdType="pmc">PMC8751645</ArticleId><ArticleId IdType="pubmed">34989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankiewicz Karita HC, Dong TQ, Johnston C, Neuzil KM, Paasche-Orlow MK, Kissinger PJ, et al. Trajectory of Viral RNA load among persons with incident SARS-CoV-2 G614 infection (Wuhan Strain) in association with COVID-19 symptom onset and severity. JAMA Netw. Open. 2022;5(1):e2142796. doi: 10.1001/jamanetworkopen.2021.42796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.42796</ArticleId><ArticleId IdType="pmc">PMC8749477</ArticleId><ArticleId IdType="pubmed">35006245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral load in samples tested by TaqPath polymerase chain reaction. J. Infect. Dis. 2021;223(10):1666–1670. doi: 10.1093/infdis/jiab082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab082</ArticleId><ArticleId IdType="pmc">PMC7928763</ArticleId><ArticleId IdType="pubmed">33580259</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Tao X. Comparison of COVID-19 and influenza characteristics. J. Zhejiang Univ. Sci. B. 2021;22(2):87–98. doi: 10.1631/jzus.B2000479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.B2000479</ArticleId><ArticleId IdType="pmc">PMC7885750</ArticleId><ArticleId IdType="pubmed">33615750</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Yao X, Zhao Y, Wu J, Huang P, Pan C, et al. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. Microbes Infect. 2020;22(6–7):236–244. doi: 10.1016/j.micinf.2020.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.05.005</ArticleId><ArticleId IdType="pmc">PMC7217786</ArticleId><ArticleId IdType="pubmed">32405236</ArticleId></ArticleIdList></Reference><Reference><Citation>Pormohammad A, Ghorbani S, Khatami A, Razizadeh MH, Alborzi E, Zarei M, et al. Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev. Med. Virol. 2021;31(3):e2179. doi: 10.1002/rmv.2179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2179</ArticleId><ArticleId IdType="pmc">PMC7646051</ArticleId><ArticleId IdType="pubmed">33035373</ArticleId></ArticleIdList></Reference><Reference><Citation>Gov.uk. Official Statistics: Surveillance of influenza and other seasonal respiratory viruses in winter 2021 to 2022. 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>